New advances in immunomodulatory therapy for chronic inflammatory demyelinating polyradiculoneuropathy
10.3760/cma.j.cn113694-20250212-00079
- VernacularTitle:慢性炎性脱髓鞘性多发性神经根神经病的免疫调节治疗新进展
- Author:
Xujun CHU
1
;
Rui WU
1
Author Information
1. 山东第一医科大学附属省立医院神经内科，济南 250021
- Publication Type:Journal Article
- Keywords:
Chronic inflammatory demyelinating polyradiculoneuropathy;
Immunomodulation;
T-lymphocytes;
B-lymphocytes;
Complement
- From:
Chinese Journal of Neurology
2025;58(10):1119-1123
- CountryChina
- Language:Chinese
-
Abstract:
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated demyelinating peripheral neuropathy characterized by symmetric limb weakness, sensory disturbances, and diminished tendon reflexes. Its pathogenesis involves the interplay of T cells, B cells, and the complement system. Current first-line therapies including intravenous immunoglobulin, corticosteroids and plasma exchange exhibit limited efficacy, with approximately 30% of patients experiencing relapse or poor treatment response. In recent years, novel immunomodulatory therapies including anti-CD20 monoclonal antibodies, neonatal Fc receptor inhibitors, complement inhibitors, Bruton tyrosine kinase inhibitors, autologous hematopoietic stem cell transplantation, and chimeric antigen receptor T-cell therapy, have emerged as promising options for refractory CIDP, ushering in a new era of immunomodulatory treatment.
